Loading
A phase 3 trial of Pembrolizumab, Carboplatin, Paclitaxel / nab-paclitaxel in endometrial cancer, run by Merck Sharp & Dohme LLC, now recruiting.
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) is a phase 3 interventional study registered as NCT06952504 by Merck Sharp & Dohme LLC, with 1123 participants planned, started 2025-05-22 and due to reach its primary completion in 2032-05-24. Interventions recorded: Pembrolizumab, Carboplatin, Paclitaxel, Docetaxel, Sacituzumab Tirumotecan. Conditions listed: Endometrial Cancer. No results are recorded here; the registry entry is the source.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Paclitaxel / nab-paclitaxel.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Paclitaxel / nab-paclitaxel.
Shares Docetaxel, Merck & Co. (MSD), Endometrial cancer, Cisplatin.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Endometrial cancer.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Cisplatin.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Carboplatin.
Shares Docetaxel, Merck & Co. (MSD), Endometrial cancer, Cisplatin.
Shares Sacituzumab tirumotecan, Docetaxel, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD).